SML3839

Danirixin

≥98% (HPLC)

• 別名: 3-{4-Chloro-2-hydroxy-3-[(3S)-piperidine-3-sulfonyl]phenyl}-1-(3-fluoro-2-methylphenyl)urea, GSK 1325756, GSK 1325756B, GSK-1325756, GSK-1325756B, GSK1325756, GSK1325756B, N-[4-Chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N′-(3-fluoro-2-methylphenyl)urea
• 実験式（ヒル表記法）: C₁₉H₂₁ClFN₃O₄S
• CAS番号: 954126-98-8
• 分子量: 441.90
• UNSPSCコード: 51111800
• UNSPSCコード: 12352200
• NACRES: NA.21

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• フォーム: powder
• 色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear (Warmed)
• 保管温度: -10 to -25°C
• SMILES記法: O=C(NC1=CC=C(C(S([C@H]2CCCNC2)(=O)=O)=C1O)Cl)NC3=C(C(F)=CC=C3)C

詳細

生物化学的／生理学的作用

Danirixin (GSK1325756) is an orally active, selective CXC chemokine receptor 2 (CXCR2) antagonist with 78-fold lower affinity toward CXCR1 (CXCR2/CXCR1 IC50 = 12.5/977 nM by competitive binding against 0.225 nM [125I] CXCL8). Danirixin blocks agonist-induced neutrophil CD11b expression in vitro (IC50 = 420/890 nM against induction by 10 nM human CXCL1/rat CXCL2 using rat/human whole blood) and prevents lung neutrophils influx in rats in vivo following aerosol lipopolysaccharide or ozone challenge (ED50 = 1.4 and 16 mg/kg, respectively).

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable